Quarterly ResultAug 11, 2026, 08:02 AM
Theriva Biologics Doses First Patients in VIRAGE2 Phase 2a Study
AI Summary
Theriva Biologics reported its second-quarter 2026 financial results and provided a corporate update, highlighting the dosing of the first patients in the VIRAGE2 Phase 2a clinical study for metastatic pancreatic cancer. The company ended the quarter with $11.3 million in cash and cash equivalents, projecting a cash runway into Q1 2027. Net loss significantly decreased to $(3.2) million for the quarter, driven by reduced general and administrative and research and development expenses.
Key Highlights
- First patients dosed in VIRAGE2 Phase 2a study for metastatic PDAC.
- Cash and cash equivalents totaled $11.3 million as of June 30, 2026.
- Company expects cash runway to extend into Q1 2027.
- Q2 2026 net loss was $(3.2) million, down from $(13.1) million in Q2 2025.
- General and administrative expenses decreased 82% to $2.0 million in Q2 2026.
- Research and development expenses decreased 35% to $1.3 million in Q2 2026.
- VIRAGE2 trial enrollment expected to complete during the second half of 2026.
- Initial VIRAGE2 pharmacodynamic and safety data anticipated by Q3 2027.
Price Impact
More from TOVX